Akebia Therapeutics is banking on two revolutionary drugs for treatment of anemia, blood vessel leakage and cancer. The Cincinnati-based biomedical company spun off of Procter & Gamble Pharmaceuticals in 2007. Since then, Akebia has focused primarily on two drugs. The first under development is designed as a safer alternative to traditional anemia treatments. The second is designed to stop blood vessel leaks and could revolutionize treatments for diseases like sepsis and acute influenza as well as the effects of Interleukin 2, a cancer drug that can cause blood vessel leaks. The company currently had 11 employees in November 2009, but as the company progresses, expects to nearly double in size.